Optruma (Raloxifene Hydrochloride)

Raloxifene hydrochloride, the active ingredient in Optruma, is a selective estrogen receptor modulator presented as an oral formulation for oral use. It is indicated for the prevention and treatment of osteoporosis in postmenopausal women and for reducing the risk of invasive breast cancer in high‑risk women.

GNH USA supplies Optruma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Optruma acts on bone metabolism and estrogen‑dependent pathways to address several clinical conditions.

Osteoporosis: improves bone mineral density and lowers fracture risk in postmenopausal women. High‑risk breast cancer: decreases the incidence of invasive breast cancer in women with elevated risk. Postmenopausal bone health: helps maintain skeletal strength and reduces bone loss.

Common Side Effects: - Hot flashes: transient feeling of warmth and sweating. - Leg cramps: muscle tightness, often in calves. - Nausea: mild gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: sensation of light‑headedness. - Swelling: peripheral edema, especially in lower limbs.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Pulmonary embolism: blockage of pulmonary arteries. - Stroke: cerebrovascular accident. - Myocardial infarction: heart attack. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Hepatic dysfunction: abnormal liver enzymes or jaundice.

Before initiating therapy, clinicians should consider several safety measures.

Assess bone density: obtain baseline DEXA scan. Screen for thromboembolic history: avoid if prior clotting events. Monitor lipid profile: periodic cholesterol checks recommended. Avoid use in pregnancy: contraindicated due to unknown fetal risk. Store at ambient temperature: keep in original container, protect from moisture.

Raloxifene may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Estrogen therapy: may diminish raloxifene efficacy. - Warfarin: increased risk of thrombotic events. - Tamoxifen: antagonistic effect on breast tissue.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma concentrations. - CYP3A4 inducers (e.g., rifampin): may lower drug levels.